These data suggest that IL-10 expression in total patient B cells can also be detected following ex vivo stimulation and confirm that higher IL-10+B cells at baseline prior to immunotherapy predict lower irAEs in an independent metastatic disease cohort. Here, IL10 is linked to metastatic neoplasm.